Friday, September 30, 2022


Biotechnology News Magazine

Electromedical Technologies Secures $1Mil for Product Expansion

Latest Posts

City of Hope to Accelerate Immunotherapy Research & Treatment Innovation with $15 Mil Gift from Ted Schwartz Family

Ted Schwartz, who is now cancer free, achieved complete remission at City of Hope in 2020 with the center's leading CAR T cell therapy after a 16-year battle with lymphoma, provided the gift to City of Hope to advance treatment options that offer better outcomes and quality of life for people living with cancer.

Neurocrine Biosciences Appoints Dr Ingrid Delaet as Chief Regulatory Officer

Prior to joining Neurocrine Biosciences, Dr Ingrid Delaet served as Senior Vice President, Regulatory Affairs at Intercept Pharmaceuticals, which she joined in 2016.

Astrea Bioseparations Introduces Nereus LentiHERO, a Fit-for-purpose Solution for Lentiviral Vector Purification

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].

At Pack Expo, Schreiner MediPharm to Debut Functional Labels Designed from More Sustainable Materials

Schreiner MediPharm advises he new label concepts are based on existing items in Schreiner MediPharm’s roster of functional labeling solutions.

February 23, 2021

Electromedical Technologies, located in Scottsdale, Arizona*, secured a $1 million investment by a fund managed by Yorkville Advisors Global, LP to complete prototype production of its WellnessPlus POD, a critical step in the Company’s product development and expansion plans.

Further details of the financing can be found in Electromedical Technologies’ recent 8-K filing.

The Company’s prototype is slated to be completed later this year and will be used in a 510(k) medical device submission with the FDA later this year. The WellnessPlus POD is positioned as a new, smaller, professional-grade wearable device for mass-market retail customers and has the ability to work with the flagship Wellness Pro+ device. Plus, it will carry a price point that is more affordable to 90 % of the population. In addition, the Company plans to introduce a program to help our Veterans and First Responders and their families to obtain a device at no upfront cost and a year of service at no charge.

Jennifer Scutti, Vice-President of Yorkville Advisors commented, “We are pleased that our investment in Electromedical Technologies will assist them in their near-term product development and expansion goals and look forward to working with management.”

Matthew Wolfson, Founder, and CEO of EMED, noted, “Securing funding for prototype production and completion of our WellnessPlus POD is a key step in our development path. We are pleased to be working with our new financial partner Yorkville Advisors to assist us in achieving this objective and help get new product development into high gear. Yorkville’s investment demonstrates confidence in Electromedical Technologies and recognition of the exciting and fast-developing field of bioelectronics.”

“EMED plans to use the prototype device in conjunction with an FDA 510(k) submission during the second half of 2021 and could begin trials at the end of the year. The Opioid epidemic is becoming even worse due to medical and social distancing and we believe that EMED is poised to help millions of people improve their quality of life without the use of opioids and drugs that can have serious adverse effects on the body. With over 10,000 of our flagship products sold over the years, we are pleased to have helped our customers with relief from their chronic pain through electrotherapy and look forward to providing comfort and relief to many more ahead.”

*Electromedical Technologies, Inc. is a commercial stage, FDA cleared, bioelectronic medical device manufacturing company initially focused on the treatment of various chronic, acute, intractable, and post-operative pain conditions. Through university collaboration agreements the company is working to develop a comprehensive research program in defining the effects of electro-modulation on the human body by studying the impacts of electrical fields in cell signaling and effects on virus assembly and immune responses with the goal of improving human wellbeing. The company’s current cleared product indications are for chronic acute post traumatic and post-operative, intractable pain relief.

Their animal studies do not involve any human testing, and are not related to their current products. The company is conducting this research to augment and advance the science of electro-modulation in healthcare. The United States Food and Drug Administration has not reviewed or approved our animal research studies.

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine